Expanded Access to Cabozantinib for Medullary Thyroid Cancer

Inclusion Criteria

• Diagnosed with medullary thyroid cancer (MTC) that cannot be surgically removed, has spread locally, or has metastasized.
• The cancer is progressing, as determined by the doctor.
• Previously treated with standard therapies for MTC, or other available treatments are not suitable.
• General health status allows participation, with a performance score of 0 to 2.
• Adequate organ and bone marrow function.
• Able to understand and follow the study requirements and has signed a consent form.
• Sexually active participants must agree to use barrier methods of contraception, like condoms, during the study and for 3 months after the last dose, even if using other birth control methods.

Exclusion Criteria

• Received chemotherapy or biological agents within 4 weeks, or certain other treatments within 6 weeks before starting cabozantinib.
• Previously participated in a cabozantinib trial, even if not treated with the drug.
• Received radiation therapy to certain areas within specific timeframes before starting cabozantinib.
• Received radionuclide treatment within 6 weeks before starting cabozantinib.
• Treated with kinase inhibitors or hormonal therapies within 14 days or longer, depending on the drug's half-life, before starting cabozantinib.
• Participated in another investigational study within 28 days before starting cabozantinib.
• Not fully recovered from side effects of previous treatments, except for hair loss or other minor effects.
• Have active brain metastases or epidural disease, with some exceptions.
• Require ongoing treatment with certain strong medications that affect liver enzymes.
• Need to take blood thinners or antiplatelet drugs, except for low-dose aspirin or similar medications.
• Have had significant gastrointestinal bleeding or coughing up blood recently.
• Have tumors affecting major blood vessels or the gastrointestinal tract.
• Have uncontrolled or serious recent illnesses, including certain heart or digestive disorders.
• Cannot swallow capsules.
• Are pregnant or breastfeeding.
• Cannot or will not follow the study protocol or cooperate with the study team.
• Have had another cancer diagnosis requiring treatment within the last two years, unless treated with curative intent and not on other cancer therapies.